Liposomal daunorubicin and cytarabine (CPX-351) was effective in relapsed acute myeloid leukemia, but long-term follow-up is needed to determine the extent of the agent's cardiotoxicity. In a study of ...

CPX-351 improved overall survival among older patients with myelodysplastic-related AML who undergo hematopoietic transplantation. CPX-351 treatment resulted in improved overall survival (OS) among ...

Intensive induction chemotherapy and HMA/VEN showed similar adjusted survival outcomes in older patients with NPM1-mutant AML. Composite complete remission rates were comparable between IC and HMA/VEN ...

Researchers compared intensive chemotherapy with single-agent clofarabine in fit older adults with newly diagnosed AML.

A panelist discusses how the highest unmet needs in acute myeloid leukemia include treatments for patients with refractory and relapsed disease, addressing poor outcomes in patients with TP53 ...

Investigation of the role of IFITM3 and the PI3K/Akt axis in the acute myeloid leukemia tumor microenvironment.

Phase 1 study of venetoclax combined with a 10-day regimen of decitabine in subjects with high-risk acute myeloid leukemia. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This ...

This releases the inhibitory state of T cells, restoring their activity so they can recognize and attack tumor cells once again. After specifically recognizing and binding to antigens on the surface ...

Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. AML can affect people of any age, but it is most common in adults. AML occurs when bone marrow produces abnormal blood cells, ...